Innovative Bispecific Nanobody Targeting ANGPT2 and VEGFA for Next-Generation Cancer Therapy

VHH-P410 is a humanized nanobody-based bispecific antibody currently in the biological testing stage, designed to target both angiopoietin 2 (ANGPT2) and vascular endothelial growth factor A (VEGFA). This dual-targeting approach leverages the complementary roles of ANGPT2 and VEGFA in tumor angiogenesis, offering a new avenue for cancer therapeutics. By precisely interrupting key pro-angiogenic pathways, VHH-P410 holds potential to limit tumor growth and vascularization, addressing significant unmet needs in cancer management.

Licensing Opportunity

VHH-P410 is open for global licensing and partnership opportunities. We welcome inquiries from biopharmaceutical companies seeking to advance innovative cancer therapeutics through collaboration and co-development.

Development Phase

Modality

VHH-P410 employs a quadrivalent, bispecific antibody modality composed of two identical polypeptide chains, each integrating receptor fragments targeting VEGFA fused to an Fc domain and sequentially connected via a flexible (G4S)4 linker to a nanobody targeting ANGPT2. This modular structure confers high stability, superior tissue penetration, and minimized immunogenicity, hallmarks of nanobody therapeutics. Expression in human embryonic kidney cells supports consistent production and post-translational fidelity. The compact size and flexible architecture of the nanobody domains enable improved tumor infiltration and access to challenging epitopes, making VHH-P410 particularly advantageous for treating cancer.

Target

ANGPT2 and VEGFA are pivotal protein targets involved in tumor vascular biology. ANGPT2, a secreted glycoprotein, and VEGFA, a key angiogenic cytokine, play essential roles in regulating blood vessel formation, stability, and remodeling. ANGPT2 and VEGFA are primarily expressed in vascular endothelial cells and are abundantly present within tumor-associated vasculature. The upregulation of ANGPT2 and VEGFA in various cancers supports tumor angiogenesis and resistance to standard therapies. Targeting both ANGPT2 and VEGFA disrupts crucial pro-angiogenic signaling networks, potentially halting tumor progression and metastasis. VHH-P410 strategically addresses ANGPT2 and VEGFA pathways, conferring significant therapeutic and commercial value in oncological drug development.

Mechanism of Action

VHH-P410 functions as a dual angiogenesis inhibitor by binding simultaneously to ANGPT2 and VEGFA. By targeting ANGPT2, VHH-P410 interferes with vascular destabilization and abnormal remodeling, while inhibition of VEGFA blocks a key driver of endothelial cell proliferation and new blood vessel formation. The combined blockade of these pathways restricts tumor-driven angiogenesis, limiting nutrient supply and tumor growth. The nanobody-based platform further provides opportunities for generating advanced derivatives, such as antibody-drug conjugates (ADCs) or multi-specific therapeutics, enhancing adaptability for oncology indications and beyond.

Cancer

Cancer remains a global health burden, encompassing a multitude of malignancies that collectively result in high morbidity and mortality. While the incidence and prevalence of cancer continue to rise worldwide, treatment modalities have evolved from conventional chemotherapy and surgery to include radiation, targeted therapies, and immunotherapies. Despite these advances, significant limitations persist—many patients face recurrence, therapy resistance, and adverse effects. The biological heterogeneity of tumors and the complexity of the tumor microenvironment contribute to variable therapeutic outcomes. Unmet clinical needs include more effective strategies for controlling tumor angiogenesis, overcoming resistance, and improving durable response rates. VHH-P410, by precisely targeting ANGPT2 and VEGFA, addresses these challenges with a dual anti-angiogenic approach, potentially transforming outcomes for patients with difficult-to-treat cancers.